This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Why Did Teva Pharmaceuticals Stock Soar Today?
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) opened more than 15% higher on Monday after the struggling drugmaker picked H. Lundbeck (HLUYY) chief Kare Schultz to fill its long-vacant CEO role.
AstraZeneca (AZN) Looks Good: Stock Adds 5.1% in Session
by Zacks Equity Research
AstraZeneca (AZN) shares rose more than 5% in the last trading session, amid huge volumes.
3 Large Cap Pharma Stocks to Buy Now
by Ryan McQueeney
The healthcare sector has dominated headlines this year thanks to promises from the GOP and the Trump administration related to repealing and replacing Obamacare. This uncertainty has not led to weak trading, and large cap pharma stocks have been among some of the biggest gainers this year. Check out these three large cap pharma stocks to buy now!
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
by Arpita Dutt
The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.
3 Large Cap Pharma Stocks to Buy Now
by Ryan McQueeney
Despite the uncertainty looming over the healthcare business, drug stocks have been doing well so far this year. Check out these three large cap pharma stocks to buy now!
4 Large-Cap Drug Stocks To Buy Post Q1 Earnings
by Arpita Dutt
Take a look at these four large-cap drug stocks including Merck (MRK) that look well-positioned post Q1 earnings.
3 Large Cap Drug Stocks to Buy Now
by Ryan McQueeney
Our overall "Medical" sector is up about 7.78% year-to-date, which just edges out the gains of the S&P 500. Within this broad sector, one of the better performing industries has been what we call "Large Cap Pharmaceuticals."
Cirrus Logic, Skechers, Valeo SA ADR, H Lundbeck AS and Quanta Services highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cirrus Logic, Skechers, Valeo SA ADR, H Lundbeck AS and Quanta Services highlighted as Zacks Bull and Bear of the Day
Don't Make It Complicated, Own Drug Stocks
by John Blank
The basic ingredients for rising drug demand -- the frailties that accompany aging -- are going to be there for the next 2 decades, in the USA and elsewhere.